Join to View Full Profile
560 W Mitchell StSte 185Petoskey, MI 49770
Phone+1 231-487-3390
Fax+1 231-487-3578
Dr. Matusz-Fisher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Ashley Matusz-Fisher, MD, is a breast medical oncology specialist based in Charlotte, NC. She graduated from Wayne State University School of Medicine in 2016 and completed her internal medicine residency at Carolinas Medical Center in 2019. Dr. Matusz-Fisher has contributed to several scholarly articles, including research on tumor lysis monitoring in chronic lymphocytic leukemia and the use of antibody-drug conjugates in breast cancer. Her work has been published in reputable journals such as JCO Oncology Practice, Annals of Translational Medicine, and Expert Opinion on Biological Therapy.
Education & Training
Carolinas Medical CenterResidency, Internal Medicine, 2016 - 2019
Wayne State University School of MedicineClass of 2016
Certifications & Licensure
MI State Medical License 2022 - 2025
NC State Medical License 2016 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 1 citationsEvaluation of the Impact of Monitoring for Tumor Lysis During Venetoclax Ramp-Up in Chronic Lymphocytic Leukemia in Routine Clinical Practice.Nilanjan Ghosh, Ashley Matusz-Fisher, Rupali Bose, Danielle Boselli, Gray Magee
JCO Oncology Practice. 2024-11-18 - 2 citationsSacituzumab govitecan and other antibody-drug conjugates targeting trophoblast cell-surface antigen 2 (Trop-2) in breast cancer.Ashley Matusz-Fisher, Antoinette R Tan
Annals of Translational Medicine. 2022-09-01 - 8 citationsCombination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer.Ashley Matusz-Fisher, Antoinette R Tan
Expert Opinion on Biological Therapy. 2021-11-21
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
